Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC

Trial Profile

Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs PBF 509 (Primary) ; PDR 001 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms AdenONCO
  • Sponsors Palobiofarma
  • Most Recent Events

    • 15 Sep 2016 Study is now evaluating PBF-509 in Combination With PDR-001. Thus changes in scientific title, purpose, phase, planned end dates, primary end points, patient no, inclusion-exclusion criteria, drug's list and treatment.
    • 15 Sep 2016 Planned number of patients changed from 15 to 92.
    • 15 Sep 2016 Planned End Date changed from 1 Oct 2017 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top